Fochon Pharmaceuticals Receives CFDA Approval for Clinical Trials of Innovative Medicine to Treat Solid Tumors

Fochon Pharmaceuticals receives CFDA approval for clinical trials of the innovative drug FCN-437 capsule, which is intended to treat solid tumors.

Until December 2017, Fochon receives the investment with approximately RMB 28 million on R&D for FCN-437.

Until January 23th, 2018, there is no medicine with independent intellectual property right launched in China (excluding Hong Kong, Macau and Taiwan) with the same targeted therapy as FCN-437.

In 2016, the global sales of similar medicine amounted to about $2.1 billion.